Literature DB >> 2551391

Isolation and characterization of biologically active murine interleukin-1 alpha derived from expression of a synthetic gene in Escherichia coli.

G O Daumy1, J M Merenda, A S McColl, G C Andrews, A E Franke, K F Geoghegan, I G Otterness.   

Abstract

A murine interleukin-1 alpha (mIL-1 alpha) gene coding for amino acids 115 to 270 of the precursor protein (Lomedico, P.T., Gubler, U., Hellmann, C.P., Dukovich, M., Giri, J.G., Pan, Y.E., Collier, K., Semionow, R., Chua, A.O. and Mizel, S.B. (1984) Nature 312, 458-462) was chemically synthesized and expressed in Escherichia coli. mIL-1 alpha, in the form of insoluble inclusion bodies, accounted for approx. 30% of total cellular protein produced by the recombinant strain. A simple isolation protocol was developed in which inclusion body material was first solubilized in 3 M guanidine hydrochloride, and the mIL-1 alpha was then simultaneously purified and allowed to fold to its active conformation by dialysis against distilled water. This procedure yielded pure, biologically active mIL-1 alpha with 41% recovery of the mIL-1 alpha present in the guanidine hydrochloride extract. The purified preparation had the expected amino acid composition, a molar absorptivity of 28,200 M-1.cm-1 and a pI of 5.2. No methionyl-mIL-1 alpha was detected by N-terminal sequence analysis, and the endotoxin level was less than 10 pg per micrograms of mIL-1 alpha. The specific biological activity was 3.10(7) units/mg in a co-mitogenic thymocyte proliferation assay. In addition to full-length mIL-1 alpha, the preparation contained N-terminally truncated mIL-1 alpha species (mainly des-4 and des-6 amino acid forms). The truncated species were isolated and found to have the same biological activity as the complete polypeptide. Thus, the active fragment of mIL-1 alpha appears to consist of a proteinase-sensitive N-terminal region which is not essential for activity, and a proteinase-resistant core which harbors the essential determinants of its cytokine function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551391     DOI: 10.1016/0167-4838(89)90115-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Preparation and extraction of insoluble (inclusion-body) proteins from Escherichia coli.

Authors:  Ira Palmer; Paul T Wingfield
Journal:  Curr Protoc Protein Sci       Date:  2004-11

2.  The use of sarkosyl in generating soluble protein after bacterial expression.

Authors:  S Frankel; R Sohn; L Leinwand
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

3.  The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis.

Authors:  A C Issekutz; A Meager; I Otterness; T B Issekutz
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

4.  Preparation and extraction of insoluble (inclusion-body) proteins from Escherichia coli.

Authors:  Ira Palmer; Paul T Wingfield
Journal:  Curr Protoc Protein Sci       Date:  2012-11

5.  Proteoglycan loss and subsequent replenishment in articular cartilage after a mild arthritic insult by IL-1 in mice: impaired proteoglycan turnover in the recovery phase.

Authors:  A A van de Loo; O J Arntz; I G Otterness; W B van den Berg
Journal:  Agents Actions       Date:  1994-05

6.  Flare-up of experimental arthritis in mice with murine recombinant IL-1.

Authors:  A A van de Loo; O J Arntz; W B van den Berg
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

7.  Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice.

Authors:  R J Griffiths; M A Smith; M L Roach; J L Stock; E J Stam; A J Milici; D N Scampoli; J D Eskra; R S Byrum; B H Koller; J D McNeish
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

8.  Changes in Mobility of the Golden Hamster with Induction of an IL-1-Induced Arthritis.

Authors:  I G Otterness; M L Bliven; A J Milici
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.